Cyrille Serve

Investment Banking

We are delighted to announce the arrival of Cyrille Serve who joins Bryan, Garnier & Co as Managing Director for Business & Tech-Enabled Services.

London, December 2021 – Bryan, Garnier & Co, a leading pan-European investment bank focusing on growth companies, is delighted to announce that Cyrille Serve has been appointed Managing Director at the firm.

Based in London, Cyrille will help further drive Bryan, Garnier & Co’s Business Services franchise across Northern and Western Europe.

Cyrille, 43, has had a 20-year career in M&A gained at Commerzbank / Dresdner Kleinwort, spent mostly in London.

In his first decade, he worked in the Italian, Food Consumer Retail, Russian and General Industrial M&A teams. Most recently, he specialised in support services with a focus on mid-market cross-border transactions in Continental Europe.

Over the 2 decades, Cyrille has worked on projects for a wide range of European clients including Aliaxis and Tessenderlo (Belgium), Engie and Vinci (France), Commerzbank and DKV Mobility (Germany), AFK Sistema and Razgulay (Russia) and Forth Ports and Pamplona Capital (UK).

Cyrille holds an MSc in Management (Grande Ecole) from HEC Paris where he majored in Finance. In parallel to HEC, Cyrille read History at Panthéon Sorbonne where he gained a BA.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for HDF Energy (Euronext Paris), Mister SPEX (Deutsche Boerse), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm), McPhy Energy (Euronext Paris), Linas Matkase (NASDAQ Stockholm), Heidelberg Pharma (Deutsche Börse), Swedish Stirling (NASDAQ Stockholm), Basilea (SIX) GenSight (Euronext Paris), and Valneva (NASDAQ / Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.